Found: 97
Select item for more details and to access through your institution.
RNA Expression-Based Analysis to Predict Response in Patients with Metastatic Mismatch Repair Proficient Colorectal Cancer Treated with Regorafenib and Nivolumab.
- Published in:
- Oncology, 2024, v. 102, n. 7, p. 549, doi. 10.1159/000535599
- By:
- Publication type:
- Article
Sequencing of Somatostatin-Receptor--Based Therapies in Neuroendocrine Tumor Patients.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 3, p. 340, doi. 10.2967/jnumed.123.265706
- By:
- Publication type:
- Article
Rethinking Dosimetry: The Perils of Extrapolated External-Beam Radiotherapy Constraints to Radionuclide Therapy.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 3, p. 362, doi. 10.2967/jnumed.123.267167
- By:
- Publication type:
- Article
Cutaneous Neuroendocrine Metastases of Visceral Origin Responsive to Surgical Resection and Targeted Radionuclide Therapy.
- Published in:
- 2024
- By:
- Publication type:
- Case Study
Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer.
- Published in:
- Cancers, 2024, v. 16, n. 3, p. 556, doi. 10.3390/cancers16030556
- By:
- Publication type:
- Article
Rethinking Dosimetry: The Perils of Extrapolated External-Beam Radiotherapy Constraints to Radionuclide Therapy.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 2, p. 1, doi. 10.2967/jnumed.123.267167
- By:
- Publication type:
- Article
Sequencing of Somatostatin-Receptor--Based Therapies in Neuroendocrine Tumor Patients.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 2, p. 1, doi. 10.2967/jnumed.123.265706
- By:
- Publication type:
- Article
Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade.
- Published in:
- Frontiers in Endocrinology, 2023, p. 1, doi. 10.3389/fendo.2023.1187870
- By:
- Publication type:
- Article
Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 12, p. 1895, doi. 10.2967/jnumed.123.266185
- By:
- Publication type:
- Article
ACTH‐secreting pancreatic neuroendocrine neoplasms: A case‐series.
- Published in:
- Journal of Neuroendocrinology, 2023, v. 35, n. 10, p. 1, doi. 10.1111/jne.13336
- By:
- Publication type:
- Article
HORMONET: a phase II trial of tamoxifen for estrogen/progesterone receptor-positive neuroendocrine tumors.
- Published in:
- Therapeutic Advances in Medical Oncology, 2023, p. 1, doi. 10.1177/17588359231186041
- By:
- Publication type:
- Article
EGFR is a potential therapeutic target for highly glycosylated and aggressive pancreatic neuroendocrine neoplasms.
- Published in:
- International Journal of Cancer, 2023, v. 153, n. 1, p. 164, doi. 10.1002/ijc.34499
- By:
- Publication type:
- Article
Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review.
- Published in:
- Journal of Nuclear Medicine Technology, 2023, v. 51, n. 1, p. 22, doi. 10.2967/jnmt.122.264904
- By:
- Publication type:
- Article
The Future of Targeted α-Therapy Is Bright, but Rigorous Studies Are Necessary to Advance the Field.
- Published in:
- Journal of Nuclear Medicine, 2023, v. 64, n. 2, p. 219, doi. 10.2967/jnumed.122.264805
- By:
- Publication type:
- Article
The Future of Targeted Alpha Therapy is Bright but Rigorous Studies are Necessary to Advance the Field.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.122.264805
- By:
- Publication type:
- Article
Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update.
- Published in:
- Cancers, 2022, v. 14, n. 17, p. 4201, doi. 10.3390/cancers14174201
- By:
- Publication type:
- Article
Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Perioperative Carcinoid Crisis: A Systematic Review and Meta-Analysis.
- Published in:
- Cancers, 2022, v. 14, n. 12, p. 2966, doi. 10.3390/cancers14122966
- By:
- Publication type:
- Article
Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review.
- Published in:
- Cancers, 2022, v. 14, n. 6, p. 1428, doi. 10.3390/cancers14061428
- By:
- Publication type:
- Article
Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors.
- Published in:
- Current Oncology, 2022, v. 29, n. 2, p. 510, doi. 10.3390/curroncol29020046
- By:
- Publication type:
- Article
Reply: Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262340
- By:
- Publication type:
- Article
Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is it an Either/Or Question?
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.263041
- By:
- Publication type:
- Article
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATE.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.120.258897
- By:
- Publication type:
- Article
Reply: Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262340
- By:
- Publication type:
- Article
Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is it an Either/Or Question?
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.263041
- By:
- Publication type:
- Article
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATE.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.120.258897
- By:
- Publication type:
- Article
Chemotherapy in Neuroendocrine Tumors.
- Published in:
- Cancers, 2021, v. 13, n. 19, p. 4872, doi. 10.3390/cancers13194872
- By:
- Publication type:
- Article
Preclinical evaluation of [<sup>225</sup>Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 11, p. 3408, doi. 10.1007/s00259-021-05315-1
- By:
- Publication type:
- Article
Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is it an Either/Or Question?
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.263041
- By:
- Publication type:
- Article
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATE.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.120.258897
- By:
- Publication type:
- Article
Reply: Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262340
- By:
- Publication type:
- Article
A phase II basket trial of Dual Anti–CTLA–4 and Anti–PD–1 Blockade in Rare Tumors (DART) SWOG S1609: High‐grade neuroendocrine neoplasm cohort.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 17, p. 3194, doi. 10.1002/cncr.33591
- By:
- Publication type:
- Article
Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT‐3 and RADIANT‐4 trials.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 15, p. 2674, doi. 10.1002/cncr.33540
- By:
- Publication type:
- Article
Untitled.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.121.262340
- By:
- Publication type:
- Article
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATE.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 8, p. 1, doi. 10.2967/jnumed.120.258897
- By:
- Publication type:
- Article
Untitled.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.121.262340
- By:
- Publication type:
- Article
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATE.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 7, p. 1, doi. 10.2967/jnumed.120.258897
- By:
- Publication type:
- Article
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATE.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 6, p. 1, doi. 10.2967/jnumed.120.258897
- By:
- Publication type:
- Article
Sensitivity and Specificity of the NETest: A Validation Study.
- Published in:
- Neuroendocrinology, 2021, v. 111, n. 6, p. 580, doi. 10.1159/000509866
- By:
- Publication type:
- Article
A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with <sup>177</sup>Lu-DOTATATE.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 5, p. 1, doi. 10.2967/jnumed.120.258897
- By:
- Publication type:
- Article
An Update on the Management of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH).
- Published in:
- 2021
- By:
- Publication type:
- journal article
Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki‐67 Is ≥10%?
- Published in:
- Oncologist, 2021, v. 26, n. 4, p. 294, doi. 10.1002/onco.13633
- By:
- Publication type:
- Article
Desmoplastic mesenteric lesions do not respond radiographically to peptide receptor radionuclide therapy.
- Published in:
- Journal of Neuroendocrinology, 2021, v. 33, n. 2, p. 1, doi. 10.1111/jne.12936
- By:
- Publication type:
- Article
Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide.
- Published in:
- Oncologist, 2021, v. 26, n. 2, p. 115, doi. 10.1002/onco.13611
- By:
- Publication type:
- Article
Peptide Receptor Radionuclide Therapy (PRRT) during the COVID-19 pandemic: are there any concerns?
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.249136
- By:
- Publication type:
- Article
Risk of bowel obstruction in patients with mesenteric/peritoneal disease receiving peptide receptor radionuclide therapy (PRRT).
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.120.242875
- By:
- Publication type:
- Article
Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
- Published in:
- Journal of Clinical Medicine, 2020, v. 9, n. 11, p. 3655, doi. 10.3390/jcm9113655
- By:
- Publication type:
- Article
Peptide Receptor Radionuclide Therapy (PRRT) during the COVID-19 pandemic: are there any concerns?
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.120.249136
- By:
- Publication type:
- Article
Risk of bowel obstruction in patients with mesenteric/peritoneal disease receiving peptide receptor radionuclide therapy (PRRT).
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.120.242875
- By:
- Publication type:
- Article